Ipsen has reported the failure of … trial, which evaluated its investigational drug fidrisertib in patients with the … closure of the study. However, Ipsen notes that fidrisertib was generally …

… fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends … inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability …

… fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends … inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability …

… proposer nos médicaments aux patients dans plus de 100 pays. Ipsen est … la réglementation de l’industrie pharmaceutique et de la législation en … brevets d’Ipsen et d’autres protections concernant les médicaments novateurs ; et …

… monitoring, and drug selection and optimization … medications for pruritus). From the specialty pharmacy perspective, pharmacists … geographic distribution, and health care providers. Hepatol … information. Cambridge, MA: Ipsen Biopharmaceuticals, Inc; June 2024 …

… pharmaceutical giants offering a range of drug classes and medical … dominance of established pharmaceutical and medical device companies with … Spine Technologies, Persica Pharmaceuticals Inc, Ipsen Pharma, Bayer HealthCare Pharmaceuticals Inc, Biotronik SE …

… of the department of internal medicine at the University of Nebraska … Medical Center, discussed the key factors … , Instil Bio, Ipsen, Janssen, Kite, Loxo, Miltenyi, MorphoSys, Novartis, Nurix, Pharmacyclics, Regeneron …

… of serious health problems. Researchers say the drug likely increases … in BMJ Evidence-Based Medicine. The analysis also points … Ahmad Barakji, Emil Ørskov Ipsen, Christian Gluud, Ole Mathiesen … October 2025, BMJ Evidence-Based Medicine. DOI: 10.1136…

… in its North American business. Ipsen shares fall as much as … trial evaluating its experimental oral drug for an ultra-rare bone …